Payment overview · 2025
General Payments
$429.69
19 reported records · 11 companies
Healthcare provider profile · identity verified
John L Redman, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANAHUAC, TX · NPI 1356522759
Verified facts
What the public records show
CMS Open Payments records show John L Redman, MD received $429.69 in general payments during 2025 across 19 reported records.
Axsome Therapeutics, Inc. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $81.08 | 18.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.37 | 17.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.27 | 13.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.50 | 12.4% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.40 | 8.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $34.21 | 8.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $33.08 | 7.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.21 | 4.0% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.05 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.96 | 3.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.56 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $429.69 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $81.08 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $74.37 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.27 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $34.21 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $33.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 194 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
177 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
194 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 661 | 160 |
| Gabapentin | Gabapentin | 421 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 68 |
| Furosemide | Furosemide | 277 | 68 |
| Lisinopril | Lisinopril | 274 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 50 |
| Losartan Potassium | Losartan Potassium | 226 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 55 |
| Omeprazole | Omeprazole | 216 | 45 |
| Metformin Hcl Er | Metformin Hcl | 203 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 194 | 50 |
| Ozempic | Semaglutide | 194 | 34 |
| Farxiga | Dapagliflozin Propanediol | 177 | 28 |
| Tramadol Hcl | Tramadol Hcl | 175 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 53 |
| Metformin Hcl | Metformin Hcl | 169 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 41 |
| Allopurinol | Allopurinol | 159 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 45 |
| Meloxicam | Meloxicam | 155 | 36 |
| Montelukast Sodium | Montelukast Sodium | 134 | 31 |
| Potassium Chloride | Potassium Chloride | 128 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 37 |
| Trazodone Hcl | Trazodone Hcl | 128 | 31 |
| Jardiance | Empagliflozin | 126 | 23 |
| Sertraline Hcl | Sertraline Hcl | 119 | 27 |
| Glimepiride | Glimepiride | 110 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 21 |
| Eliquis | Apixaban | 98 | 18 |
| Nifedipine Er | Nifedipine | 94 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 27 |
| Trulicity | Dulaglutide | 91 | 13 |
| Bupropion Xl | Bupropion Hcl | 89 | 24 |
| Valsartan | Valsartan | 89 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 21 |
| Carvedilol | Carvedilol | 77 | 17 |
| Ezetimibe | Ezetimibe | 75 | 14 |
| Simvastatin | Simvastatin | 75 | 17 |
| Ondansetron Odt | Ondansetron | 69 | 27 |
| Alprazolam | Alprazolam | 65 | 12 |
| Sucralfate | Sucralfate | 65 | 17 |
| Atenolol | Atenolol | 64 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 59 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 14 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 13 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 40 |
| Ibandronate Sodium | Ibandronate Sodium | 44 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 22 |
| Pregabalin | Pregabalin | 41 | 12 |
| Temazepam | Temazepam | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | suppressed |
| Famotidine | Famotidine | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Prednisone | Prednisone | 36 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 19 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Nystatin | Nystatin | 32 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 13 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Baclofen | Baclofen | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $429.69 · 19 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, Dexcom G6 Transmitter, INSPIRE, Jornay PM, Kerendia, NEXPLANON, NUZYRA, Ozempic, Qelbree, Rybelsus, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error